Online inquiry

IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1569MR)

This product GTTS-WQ1569MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets BMP10&GDF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014482.3; NM_016204.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27302; 2658
UniProt ID O95393; Q9UK05
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1569MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12003MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ2679MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ9014MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ7441MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ14313MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ15173MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ11726MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ13617MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA R1450
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW